

VIVO™

CANNABIS



Corporate Presentation

Autumn 2018

TSX-V: VIVO | OTCQX: VVCIF

DISCLAIMER

Certain information included in this presentation, which is dated as of September 25, 2018, constitute “forward-looking statements” or “forward-looking information” as defined in applicable Canadian securities laws. Any forward-looking statements speak only as of such date, and include any information as to future financial or operating performance and other statements that express expectations or estimates of the future performance of VIVO Cannabis Inc. and its subsidiaries (collectively, “VIVO” or the “Company”) The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Forward-looking statements in this presentation include statements regarding: that the Company is well positioned for growth; the Company’s proposed capital allocation priorities; timing of expected GMP certification; potential health benefits of cannabis; expected future growth of the regulated cannabis market; VIVO’s product differentiation; projected revenues; VIVO’s proposed capacity and international expansion plans; the expected timing of launch of Harvest Medicine’s telemedicine app and the expected benefits thereof; the expected benefits of VIVO’s recent acquisition of Canna Farms Limited (“Canna Farms”); the expected success and timing of VIVO’s product development activities; VIVO’s proposed growth plan, including timing of international license applications; and VIVO’s potential future revenue drivers. In addition, this presentation contains future oriented financial information (“FOFI”), including statements regarding expected capital expenditures and revenue projections, which speak only as of the date of this presentation. The FOFI has been prepared by management based on assumptions including that the Company will be able to obtain necessary approvals to proceed with its business plan; that the Company will follow regulatory requirements; that there will be no adverse changes to applicable laws and regulatory requirements; and that management will be able to execute the Company’s business plan as expected. FOFI and forward-looking statements are intended to provide prospective investors with an outlook on the Company’s activities and information pertaining to the Company’s longer-term objectives, and may not be appropriate for other purposes.

By their very nature, forward-looking statements and FOFI involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that forward-looking statements and FOFI will not be achieved. Certain material factors or assumptions are applied in FOFI and making forward-looking statements and FOFI, and actual results may differ materially from those expressed or implied in such statements. The Company cautions readers not to place undue reliance on these statements, as many important factors, many of which are beyond the Company’s control, could cause actual results to differ from the expectations expressed in such forward-looking statements or FOFI. These factors include, but are not limited to, risks related to: the future evolution of the regulated cannabis market; industry, competition, customer, legal, taxation and accounting matters; adverse industry events; general economic conditions; loss of potential markets; future legislative and regulatory developments; that the Company may not derive the expected benefits of the Canna Farms acquisition; inability to access sufficient capital to pursue business objectives on favorable terms or at all; the ability of the Company to implement its business plan; competition; product liability; crop failure; and other factors beyond the control of the Company. The foregoing list of factors that may be affect future results is not exhaustive. When reviewing the Company’s forward-looking statements and FOFI, readers should carefully consider the foregoing factors and other risks, uncertainties and potential events, including those set out in the Company’s annual information form dated April 30, 2018. The Company does not intend, and disclaims any obligation, to update any forward-looking statements or FOFI, whether written or oral, or whether because of new information or otherwise, except as may be required by law.

This presentation also includes information obtained by the Company from third parties, including, but not limited to, information regarding market data and the potential health benefits of cannabis. The Company believes such information to be accurate but has not independently verified such information. There is a risk that the assumptions made, and conclusions drawn, by the Company based on such third-party information are not accurate. Further, Health Canada has advised that cannabis is not an approved therapeutic drug in Canada and that, at present, while pointing to some potential therapeutic benefits, the scientific evidence does not establish the safety and efficacy of cannabis to the extent required by the Food and Drug Regulations for marketed drugs in Canada unless a specific cannabis product has received a notice of compliance from Health Canada and a Drug Identification Number (DIN).

WELL-POSITIONED FOR GROWTH

Approximately \$100 million in cash, with the following capital allocation priorities:



Promotion of premium
medical and adult-use
brands



Scale-up medical
clinic platform



Product
development
and innovation



Production
capacity and
capability

BUSINESS FOUNDATION

A balance of entrepreneurial spirit & corporate discipline

Values

Creativity, Accountability, Respect, Excellence, Speed

Mission

To supply high-quality, trusted and innovative cannabis products and services that make people feel better.


Vision

To be an internationally respected cannabis company recognized for high-quality, trusted and innovative products and services.



REVENUE PROJECTIONS

**International Market Focus:
Europe and Australia**



\$1M ————— **Company Revenue** —————→ **\$500M**

\$0.5B ————— **Global Market Opportunity** —————→ **\$50B**

*Management forecast – see Disclaimer on slide 2

PRIORITIES AT A GLANCE



**Disciplined
Execution**



**Proprietary
Technology**



**Capacity
Expansion**



**Go-to-Market
Initiatives**



**Customer-Focused
Culture**



**Local & Global
Expansion**

LEADERSHIP TEAM



EXCEPTIONAL EXECUTIVE TEAM

Track record of building sustainable businesses and executing growth strategies



Barry Fishman

Chief Executive Officer

20 years as a business leader, most recently as CEO of European-focused specialty pharmaceutical company Merus Labs. Previously served as CEO of both Teva Canada and Taro Canada.



Dr. Michael Bumby

Chief Financial Officer

20 years of experience in pharmaceuticals, previously CFO of three publicly held Canadian companies - most recently as CFO of Merus Labs.



Ray Laflamme

SVP, Facilities and Engineering

45 years of engineering, design, construction, project management experience. Commissioned several industrial food grade facilities in North America including the Canna Farms' facility.



Daniel Laflamme

President, Canna Farms

Over 15 years of financial, operational and regulatory business experience. Prior to founding CF, was Managing Director for Amberwood Homes.

EXCEPTIONAL EXECUTIVE TEAM

Experience in operations, product development, branding, and demand creation



Andrew LaCroix

VP, International and General Counsel

Over 20 years of legal experience starting at Stikeman and then his own legal practice.



Joel Mallard

Chief Customer Officer

20 years of sales and marketing experience at Diageo and Cowbell Brewing Co.



Shekhar Parmar

CEO, Harvest Medicine and Chief Strategy Officer

Over 10 years of experience as an entrepreneur, lawyer, and design thinker.



Sung Kang

Chief Marketing Officer

Over 15 years of senior marketing at Labatt's, General Mills and Novartis Consumer.

BOARD OF DIRECTORS

Proven leaders in governance, corporate oversight policy influence and capital markets



Paul Lucas (Chairman)

Former CEO of Glaxo Canada with significant board experience in for-profit & non-profit sectors.



Barry Fishman (CEO)

Former CEO of Merus Labs, Teva Canada and Taro Canada, Vice President of Marketing at Eli Lilly.



Daryl Kramp

Member of Parliament, Municipal Counsellor, and successful entrepreneur.



Richard Fitzgerald

Former CEO & Chairman of Diageo Canada – broad leadership experience in alcohol and tobacco.



Daniel Laflamme

Co-founder of Canna Farms. Seasoned entrepreneur with broad cultivation and operational experience.



Aaron Keay

Creative capital markets expert with deep experience M&A and take-public transactions.



John Easson

Corporate finance and M&A Advisor – experiences ranging from start-ups to Canada's largest public companies.

SCIENTIFIC ADVISORY BOARD

Three key global leaders: cannabis research, clinical experience and plant science



Raphael Mechoulam, PhD

The world-renowned cannabis scientist that discovered tetrahydrocannabinol (THC) and cannabidiol (CBD).



Donald I. Abrams, MD

Cancer and integrative medicine specialist. Co-Author of The Chapter Cannabinoids and Cancer in the Oxford University Press.



Mike Dixon, PhD

Leading globally recognized plant scientist – specializing in controlled environmental systems.





1 + 1 = 3
**TRANSFORMATIONAL
ACQUISITION**

CANNA FARMS ACQUISITION

Deal Summary

- VIVO acquired 100% of the issued and outstanding common shares of Canna Farms on August 31, 2018
- Nearly triples VIVO's current capacity to provide key supply in a potentially underserved market and adds over 15,000 medical patients
- Addition of new indoor West Coast indoor cultivation facility in Hope, BC
- Immediately accretive – Canna Farms generated net revenue and adjusted EBITDA of \$9.4 million and \$4.3 million, respectively, for the twelve months ending June 30, 2018¹

TRANSACTION VALUE
\$133 million²

CONSIDERATION
92.5 million in VIVO Shares
(vesting over 30 months)
\$22.5 million in cash

POST-CLOSE OWNERSHIP (BASIC)
VIVO Shareholders: 68%
Canna Farms Shareholders: 32%

¹ Unaudited; adjusted EBITDA based on EBITDA before changes in fair value of biological assets

² Based on 20-day VWAP of \$1.20 as at July 27, 2018

COMBINING OUR STRENGTHS



Great People
& Proprietary
Insights

Target Unmet Needs
with Stronger Branding
& Positioning

Innovative
New Product
Development

Sales Execution
& Market Access

PROFITABLE
GROWTH

Experienced
management team
with BC & ON footprint

Strong premium
brands with
quality focus

Award-winning strains
and future novel
dosage forms

Combined strengths
provide greater
market access





**PRODUCTION
QUALITY**



QUALITY MATTERS

VIVO has been growing and selling pharmaceutical-grade medical cannabis since 2016 in a “quality-first” culture.

Our state-of-the-art indoor grow facility in Ontario is a precision-controlled environment that is one of the most technologically-advanced in the world. We are ISO 9001 certified and expect GMP certification in late 2018.

Our world-class cannabis R&D lab is also developing proprietary strains and advanced growing techniques in partnership with some of the brightest minds in agriculture at the University of Guelph.



Barry Fishman
Chief Executive Officer

VIVO has invested in technology, people and processes that support an unwavering commitment to quality



INCREASED CAPACITY

Annual funded capacity of 57,000 kilograms, with multiple supply agreements

	<u>Location</u>	<u>Current Capacity</u>	<u>End of 2018 Capacity</u>	<u>Future Capacity</u>
	Napanee, ON	1,500 kgs	5,500 kgs	32,500 kgs
	Hope, BC	2,700 kgs	6,900 kgs	24,500 kgs
Pro Forma Capacity		4,200 kgs	12,400 kgs	57,000 kgs (mid 2020)

Nearly triples VIVO's current capacity



PRECISELY CONTROLLED

Every variable is controlled to produce high-quality, consistent cannabis product

**Exclusive Cannabis R&D Partnership
with University of Guelph**

Advanced Technology | Pharmaceutical-Grade

1. Air Quality
2. CO2 Levels
3. Oxygen Levels
4. Water Quality and Volume
5. Light Spectrum and Cycles
6. Temperature and Humidity
7. Plant Nutrition
8. Climate Controlled Curing Process



BEST-IN-CLASS TECHNOLOGY

VIVO utilizes small-batch cultivation rooms to perfectly control the growing environment in craft-like conditions.



DIFFERENTIATION





WHAT SETS VIVO APART?

Formula for Success

Customer Insights

+

Innovative Development

+

Quality Products

+

Focused Execution

=

PROFITABLE GROWTH

OUR PORTFOLIO IS COMPREHENSIVE

VIVO addresses each need state with four premium brands

Improve Health



Calm My Mind



Enjoy The Moment





Beacon is the clear path to medical cannabis

- Pharmaceutical-grade products grown in small batches at our state-of-the-art facility
- Unique and simplified approach to navigating medical cannabis using the Beacon Cannatypes[™] classification system
- Rich resource of “Cannabis 101” information, media and education at beaconmedical.ca
- Wide range of pricing, special offers and referral bonuses’ for patients





CANNA FARMS

Canna Farms embraces the rich cannabis culture and craft cultivation history in British Columbia and offers a large selection of award-winning products

- The first licensed producer in BC growing since 2014
- Award winning, artisan and hand-trimmed products
- Organically grown with glacial-fed groundwater
- Over 15,000 registered patients

CANNA FARMS AWARDS

Multiple Lift Cannabis Awards:
51 Strains, 5 Oils Varieties



THC Flower
Silver (2017)



Blended/Value Variety
Gold (2016)




Hybrid Flower
Silver (2016)




High CBD Oil
Bronze (2017)



Blended/Value Variety
Bronze (2017)



High CBD Flower
Silver (2017)



THC Oil
Bronze (2016)



High CBD Flower
Bronze (2015)



LUMINA™

Lumina helps cultivate a deeper connection to one's self and promotes a healthy mind and body

Lumina is dedicated to wellness and therefore all of its products are non-combustible. Our initial suite of products will comprise three high-concentration, premium cannabis oils in THC, Balanced and CBD varieties. In the future, additional extracted product forms will be launched, such as cannabis-infused creams, lotions, aromatherapy, athletic recovery, and bath & beauty products for those seeking an elevated state of self-care.



FIRESIDE™

CANNABIS

Fireside brings friends together with a high quality line of premium cannabis that is geared towards groups

Fireside simplifies the approach to premium craft cannabis by offering three core varieties of dried flower and pre-rolled joints according to THC and CBD content. Consumers can tailor their purchases based on group size: large groups will want high potency **Fireside Black**, while medium sized groups will love **Fireside Red**, and smaller groups and couples are the perfect match for **Fireside Gold**.


ADULT-USE: RETAIL MARKET ACCESS

Provincial Governments

- Ontario
- Alberta
- British Columbia
- Manitoba
- Saskatchewan
- Yukon

Private Retailers

- Choom supply agreement
- Westleaf (Prairie Records) supply agreement
- Others in discussion



MEDICAL CANNABIS CLINICS



MEDICAL CANNABIS CLINICS



HARVEST
MEDICINE

- Education focused, patient-centric, cannabis discovery center and clinic
- Over 15,000 active patients in flagship location
- One of Canada's most successful and fastest growing cannabis clinics
- Expand patient base with additional locations and telemedicine platform

Edmonton



Calgary





TELEMEDICINE: HMED CONNECT

Simplified, quick access to a professional healthcare team, on-demand education and support for those entering the medical cannabis system.

- Class-leading educational and instructional experience
- An effective and efficient way to guide patients through their patient journey from the convenience of their homes.
- Expected to benefit pharmacies, long-term care facilities and retirement homes.



Download
App



Get Assessed
& Educated



Register
with LP



Get Medical
Cannabis

OTHER BUSINESS



INTERNATIONAL UPDATE



Germany

Stability program initiated for Germany

GMP certification on track for Q4 2018

New tender submission in October

Targeting distribution license by year-end




Australia

Pain study design initiated through leading Melbourne Pain Clinic


First patients to be enrolled in Q4 2018

Patients currently being treated with VIVO products through Special Access Scheme

PRODUCT DEVELOPMENT FOCUS



* Includes Product Development Agreement with **Pharmascience**



SOCIAL RESPONSIBILITY

Making a Difference...

VIVO began supporting the cost of treatment for a boy named Gage several years ago. He has a rare and incurable neurological disorder, as well as a rare form of epilepsy.

“We were told his seizures would never be under control,” Kelly (Gage’s mother) said “Now, he's more alert, more interactive and more social. Cannabis therapy has changed Gage’s life!”





CAPITALIZATION SUMMARY

As of September 25, 2018 – CAD Millions

Common Shares Outstanding	287
Debentures (\$3.47 w/average exercise price)	10.9
Warrants (\$1.66 w/average exercise price)	20.2
Options/RSU's	11.9
Total Issued and Outstanding	330
Daily Volume	>1
Market Cap	~\$450
Cash Balance	~\$100

STRATEGIC PRIORITIES

1. Premium Quality
2. Targeted Brands
3. Product Innovation
4. Broad Distribution
5. Competitive Costs
6. Strategic Partnerships



VIVO™

CANNABIS



Chief Executive Officer

Barry Fishman
416.662.5509
barry.fishman@vivocannabis.com

Chief Financial Officer

Dr. Michael Bumby
905.726.0995
michael.bumby@vivocannabis.com

